People: Gilead Sciences, Inc. (GILD.O)
GILD.O on Nasdaq
46.30USD
9 Feb 2010
46.30USD
9 Feb 2010
Price Change (% chg)
$0.21 (+0.46%)
$0.21 (+0.46%)
Prev Close
$46.30
$46.30
Open
--
--
Day's High
$47.00
$47.00
Day's Low
$46.05
$46.05
Volume
9,495,990
9,495,990
Avg. Vol
13,258,716
13,258,716
52-wk High
$52.29
$52.29
52-wk Low
$40.62
$40.62
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Martin, John | 57 | 2008 | Chairman of the Board, Chief Executive Officer |
| Milligan, John | 48 | 2008 | President, Chief Operating Officer |
| Washington, Robin | 46 | 2008 | Chief Financial Officer, Senior Vice President |
| Bischofberger, Norbert | 53 | 2007 | Executive Vice President - Research and Development, Chief Scientific Officer |
| Young, Kevin | 51 | 2004 | Executive Vice President - Commercial Operations |
| Alton, Gregg | 43 | 2009 | Executive Vice President - Corporate and Medical Affairs |
| Metza, Kristen | 49 | 2007 | Senior Vice President - Human Resources |
| Denny, James | 76 | 2008 | Lead Independent Director |
| Davignon, Etienne | 77 | 1990 | Director |
| Moore, Gordon | 80 | 1996 | Director |
| Berg, Paul | 82 | 1998 | Director |
| Wilson, Gayle | 66 | 2001 | Director |
| Moore, Nicholas | 67 | 2004 | Director |
| Cogan, John | 83 | 2005 | Director |
| Madigan, John | 71 | 2005 | Director |
| Hills, Carla | 75 | 2007 | Director |
| Whitley, Richard | 63 | 2008 | Director |
| Lofton, Kevin | 2009 | Director | |
| Wold-Olsen, Per | 62 | 2010 | Director |
Biographies
| Name | Description |
|---|---|
| Martin, John | John C. Martin was appointed as Chairman of the Board of Gilead Sciences Inc in May 2008 and has served as the Chief Executive Officer and a member of the Board since April 1996. Prior to joining the company, Dr. Martin held several leadership positions in the antiviral chemistry division at Bristol-Myers Squibb Company and Syntex Corporation from 1978 until 1984. He is a member of the Presidential Advisory Council on HIV/AIDS and a director of Gen-Probe Incorporated. Dr. Martin has been a member of the board of directors of the California Healthcare Institute since 2003, and currently serves as Chairman of the Board, a position he also held from 2005 to 2006. He served as President of the International Society for Antiviral Research from 1998 to 2000. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies. |
| Milligan, John | John F. Milligan is Gilead’s President, Chief Operating Officer of Gilead Sciences Inc. Dr. Milligan also joined Gilead in 1990, as a Research Scientist, and in 1996, he became Director of Project Management and Project Team Leader for the collaboration with F. Hoffmann-La Roche Ltd on Tamiflu®. In 1998, he transitioned to Corporate Development and, in March 2000, he was promoted to Vice President, Corporate Development with responsibility for licensing, corporate partnerships and mergers and acquisitions. Dr. Milligan was promoted to Chief Financial Officer in March 2002. He was promoted to Executive Vice President and Chief Financial Officer in July 2003, to Chief Operating Officer in March 2007 and to President in May 2008. Dr. Milligan received a Ph.D. in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco. |
| Washington, Robin | Robin L. Washington is Chief Financial Officer, Senior Vice President of Gilead Sciences, Inc. Ms. Washington joined the company in May 2008. Prior to joining the company, Ms. Washington served as Chief Financial Officer of Hyperion Solutions, an enterprise software company that was acquired by Oracle Corporation in March 2007. Ms. Washington also spent nearly 10 years at PeopleSoft, a provider of enterprise application software, most recently in the role of Senior Vice President and Corporate Controller. She previously was a Director of Finance for Tandem Computers, an Accounting Analyst for the Federal Reserve Bank of Chicago and a Senior Auditor for Deloitte & Touche. Ms. Washington holds a bachelor’s degree in business administration from the University of Michigan and an MBA from Pepperdine University. She currently serves on the board of directors of MIPS Technologies, Inc. |
| Bischofberger, Norbert | Norbert W. Bischofberger is Executive Vice President, Research and Development and Chief Scientific Officer of Gilead Sciences Inc. Dr. Bischofberger joined the company in 1990 as Director of Organic Chemistry, became Vice President of Organic Chemistry in February 1993 and was named Vice President of Research in August 1995. Dr. Bischofberger was appointed Senior Vice President, Research in January 1998. Dr. Bischofberger was named Senior Vice President, Research and Development in January 2000. He was promoted to Executive Vice President, Research and Development in November 2000 and to Chief Scientific Officer in March 2007. Prior to joining the company, Dr. Bischofberger was a senior scientist in Genentech, Inc.’s DNA Synthesis group from 1986 to 1990. He received his B.S. in Chemistry at the University of Innsbruck in Austria and his Ph.D. in Organic Chemistry at the Eidgennossische Technische Hochschule (ETH) in Zurich, Switzerland and did postdoctoral work at Harvard University. |
| Young, Kevin | Kevin Young is Executive Vice President, Commercial Operations of Gilead Sciences, Inc. Mr. Young joined the company in September 2004 as Executive Vice President of Commercial Operations. Mr. Young has 25 years of experience in the biopharmaceutical industry, holding positions previously at Amgen, Inc. and Zeneca Pharmaceuticals (formerly ICI Pharmaceuticals). During his 12 years at Amgen, Mr. Young held a number of positions in Europe and the United States, most recently as Head of the U.S. Inflammation Business Unit, leading the re-launch of Enbrel® following the acquisition of Immunex Corporation. He is a member of the board of Interplast, the first international humanitarian organization to provide free reconstructive plastic surgery in developing countries. Mr. Young has undergraduate and graduate degrees in sports science and exercise from Liverpool John Moores University and Nottingham University in England and has completed the Executive Program at the University of Michigan. |
| Alton, Gregg | Mr. Gregg H. Alton has been appointed as Executive Vice President - Corporate and Medical Affairs of Gilead Sciences, Inc effective August 3, 2009. He has served as Senior Vice President and General Counsel of Gilead Sciences Inc. Mr. Alton joined the company in 1999, and was promoted to his current role in 2005. From 2001 until 2005, Mr. Alton served as the Vice President and General Counsel. From 1999 until 2001, Mr. Alton served as Associate General Counsel. Prior to joining the company, Mr. Alton was an attorney at the law firm of Cooley Godward Kronish LLP. In this role, Mr. Alton’s practice focus was mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the board and treasurer of the AIDS Healthcare Foundation, a member of the board of Oculus Innovative Sciences, Inc. and a member of the board of BayBio, a San Francisco Bay Area life sciences industry organization. He received his Bachelor of Arts in Legal Studies from the University of California at Berkeley and his Juris Doctor from Stanford Law School. |
| Metza, Kristen | Kristen M. Metza is Senior Vice President, Human Resources of Gilead Sciences Inc. Ms. Metza joined the company as Vice President, Human Resources in 2006 and was promoted to her current role in July 2007. Prior to joining the company, Ms. Metza was Senior Vice President of Human Resources for Abgenix and Vice President of Human Resources for Applied Biosystems and Quantum Corporation. Ms. Metza received a B.A. in history and business administration, and completed her graduate work in industrial relations and organizational psychology at the University of Minnesota, Carlson School of Management. |
| Denny, James | James M. Denny joined the Board of Gilead Sciences Inc in 1996 and served as Chairman of the Board from 2001 to May 2008. He was appointed to serve as the lead independent director of the Board in May 2008. He served as the Chief Financial Officer and subsequently Vice Chairman of Sears, Roebuck & Co., a multi-line retailer that offers a wide array of merchandise and related services, with oversight responsibility for many of the company’s operations and staff functions. He previously served as Executive Vice President and Chief Financial and Planning Officer of G.D. Searle & Co., Chairman of Pearle Health Services, Inc., Senior Advisor at William Blair Capital Partners, Treasurer at the Firestone Tire & Rubber Co., and associate counsel at Dewey Ballantine Bushly and Wood in New York and Paris. Mr. Denny is currently a director of GATX Corporation and a member of the advisory boards for several privately-held fund management companies. He is a past Chairman of Northwestern Memorial Hospital and the Northwestern Memorial Foundation and has held directorships at Astra AB, ChoicePoint, Inc., The Principal Financial Group, The Allstate Corporation, and General Instruments, Inc. |
| Davignon, Etienne | Mr. Davignon joined the Board of Directors of Gilead Sciences Inc in September 1990. He is currently Vice Chairman of Suez-Tractebel, a utility holding company and one of the world’s top independent power producers, where he has served since 2003. He previously served as Chairman of Société Générale de Belgique, a diversified financial and industrial company. Mr. Davignon served as the European Community’s Commissioner for Industry and International Markets and as the European Community’s Vice President for Research, Industry and Energy Policies. Mr. Davignon is Chairman of Recticel, CMB and SN Air Holding and a director of Compagnie de Suez and Sofina. |
| Moore, Gordon | Mr. Nicholas Moore joined the Board of Directors of Gilead Sciences Inc in January 1996, and served as a member of the company Business Advisory Board from July 1991 until January 1996. Dr. Moore retired from Intel Corporation, the world’s largest semiconductor chip maker, where he was a co-founder and previously served as Chairman, President and Chief Executive Officer. Dr. Moore is a former Chairman and now Senior Trustee of the California Institute of Technology, a member of the National Academy of Engineering and a Fellow of the Royal Society of Engineering (UK). Among his awards, he received the National Medal of Technology and the Presidential Medal of Freedom. |
| Berg, Paul | Paul Berg joined the Board of Directors of Gilead Sciences Inc in April 1998. He served as Professor and Chairman of the Department of Biochemistry at Stanford University School of Medicine and was, until 2000, Director of the Beckman Center for Molecular and Genetic Medicine. He is also a director and scientific advisor to Affymetrix Inc. and Burrill and Company. He is a member of the U.S. National Academy of Sciences and was awarded the National Medal of Science in 1983 and the Nobel Prize in 1980 for his fundamental studies of the biochemistry of nucleic acids. |
| Wilson, Gayle | Mrs. Wilson joined Gilead’s Board of Directors of Gilead Sciences Inc in October 2001. Wife of former Governor Pete Wilson, Mrs. Wilson served as California’s First Lady from 1991 to 1999. Mrs. Wilson is a director of the College Access Foundation of California and the Ralph M. Parsons Foundation, a non-profit organization that provides higher education, social impact, civic and cultural issues and health grants. She is also the Chair of the Advisory Board of the California State Summer School for Math and Science, a member of the Board of Trustees of the California Institute of Technology, a community member to the board of the San Diego Consortium for Regenerative Medicine and a member of the board of the Burnham Institute for Medical Research. |
| Moore, Nicholas | Nicholas G. Moore joined the Board of Directors of Gilead Sciences Inc in March 2004. Mr. Moore is the retired global Chairman of PricewaterhouseCoopers LLP, a professional services firm formed in July 1998 by the merger of Coopers & Lybrand and Price Waterhouse. Prior to the merger, Mr. Moore was elected Chairman and Chief Executive Officer of Coopers & Lybrand (U.S.) in 1994 and Coopers & Lybrand International in 1997. Mr. Moore is a director of Bechtel Group, Inc., Network Appliance Inc., Wells Fargo & Company and two venture capital-backed, technology companies. He also has served as Chairman of the board of trustees of St. Mary’s College of California. Mr. Moore is a member of the American Institute of Certified Public Accountants, the California Bar Association, and the California and New York Society of Certified Public Accountants. |
| Cogan, John | John F. Cogan joined Board of Directors of Gilead Sciences Inc in July 2005. Dr. Cogan is currently the Leonard and Shirley Ely Senior Fellow at the Hoover Institution and a Professor in the Public Policy Program at Stanford University, where he has had a continuing appointment since 1980. Dr. Cogan’s current research is focused on U.S. budget and fiscal policy, social security and health care. Dr. Cogan has held a number of positions in the U.S. government, including Assistant Secretary for Policy in the U.S. Department of Labor and Associate Director and Deputy Director in the U.S. Office of Management and Budget. Dr. Cogan is a director of Monaco Coach Corporation and Venture Lending and Leasing Inc. and a trustee of the Charles Schwab Family of Funds. |
| Madigan, John | Mr. Madigan joined the Board of Directors of Gilead Sciences Inc in December 2005. He is the retired Chairman and Chief Executive Officer of Tribune Company, a media company, operating businesses in broadcasting, publishing and on the Internet. He is also a director and former Chairman of the Robert R. McCormick Foundation and a director of Boise Cascade Holdings, L.L.C. Mr. Madigan is a former member of the Defense Business Board of the Department of Defense, an advisor to Madison Dearborn Partners and a director and former Chairman of The Chicago Counsel on Global Affairs. He also serves as a trustee of Northwestern University, Rush University Medical Center and the Paley Center for Media in New York. Mr. Madigan is a member of the Council on Foreign Relations in New York, a member and former Chairman of The Commercial Club of Chicago and a director of The Renaissance School Funds. |
| Hills, Carla | Carla A. Hills joined the Board of Gilead Sciences Inc in January 2007. Since 1993, she has served as the Chair and Chief Executive Officer of Hills & Company, International Consultants, a firm providing advice to U.S. businesses on investment, trade and risk assessment issues outside the United States. Mrs. Hills served as U.S. Trade Representative from 1989 to 1993, and was principal advisor on international trade to President George H. W. Bush. Under President Gerald R. Ford, she served as Secretary of Housing and Urban Development. Mrs. Hills is a director of TCW Group, Inc. and serves on the international advisory boards of J.P. Morgan Chase, American International Group, Rolls Royce and the Coca-Cola Company. She is also Chair of the Inter-American Dialogue and the National Committee on U.S.-China Relations, Co-Chair of the Council on Foreign Relations and the International Advisory Board of the Center for Strategic and International Studies, a member of the Executive Committee of the Peterson Institute for International Economics and the Trilateral Commission and a member of the board of the U.S.-China Business Council and the International Crisis Group. |
| Whitley, Richard | Richard J. Whitley, M. D., has been appointed to the Board of Directors of Gilead Sciences, Inc. He also serves as the Distinguished Professor, Loeb Scholar Chair in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Senior Scientist, Cancer Research and Training Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Director, Center for Emerging Infections and Emergency Preparedness (CEIEP) for the University of Alabama at Birmingham. Dr. Whitley has held responsibility for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, is a former President of the International Society of Antiviral Research, chairs the Board of Scientific Councilors for the National Center for Infectious Diseases of the U.S. Centers for Disease Control and Prevention and is President-Elect of the Board of the Infectious Disease Society of America. |
| Lofton, Kevin | Mr. Kevin E. Lofton is Director of Gilead Sciences, Inc. Mr. Lofton is currently the President and Chief Executive Officer of Catholic Health Initiatives, a Denver-based healthcare system operating the full continuum of services from hospitals to home health agencies throughout the nation. He previously served as Chief Executive Officer of two university hospitals, the University of Alabama at Birmingham Hospital and Howard University Hospital in Washington, D.C. In 2007, Mr. Lofton served as Chairman of the Board of the American Hospital Association, the nation's largest hospital trade association. Mr. Lofton currently serves on the Board of Directors of the Morehouse School of Medicine, Atlanta, and the Georgia State University J. Mack Robinson College of Business, also in Atlanta. |
| Wold-Olsen, Per | Mr. Per Wold-Olsen is the Director of Gilead Sciences, Inc. Mr. Wold-Olsen spent more than 30 years with the global research-based pharmaceutical company Merck & Co., Inc., most recently serving as President of the company's Human Health Intercontinental Division. He previously held the position of President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck. Mr. Wold-Olsen currently sits on the boards of directors of three Danish-based companies. He serves as Chairman of both Lundbeck A/S, a pharmaceutical company focused in the field of central nervous system disorders, and GN Store Nord A/S, which develops and commercializes hearing aids and headsets. He also serves on the board of Exiqon A/S, a biotech company focused on the development of research and diagnostic products. Mr. Wold-Olsen is also a member of the board of the Medicines for Malaria Venture (MMV), a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Martin, John | 10,998,000 |
| Milligan, John | 5,187,440 |
| Washington, Robin | 1,166,870 |
| Bischofberger, Norbert | 4,390,990 |
| Young, Kevin | 4,364,970 |
| Alton, Gregg | 2,682,790 |
| Metza, Kristen | -- |
| Denny, James | -- |
| Davignon, Etienne | -- |
| Moore, Gordon | -- |
| Berg, Paul | -- |
| Wilson, Gayle | -- |
| Moore, Nicholas | -- |
| Cogan, John | -- |
| Madigan, John | -- |
| Hills, Carla | -- |
| Whitley, Richard | -- |
| Lofton, Kevin | -- |
| Wold-Olsen, Per | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Martin, John | 5,629,376 | 215,869,800 |
| Milligan, John | 1,581,500 | 50,280,000 |
| Washington, Robin | 0 | 0 |
| Bischofberger, Norbert | 2,055,000 | 65,597,100 |
| Young, Kevin | 495,000 | 10,687,360 |
| Alton, Gregg | 233,136 | 9,233,440 |
| Metza, Kristen | 0 | 0 |
| Denny, James | 0 | 0 |
| Davignon, Etienne | 0 | 0 |
| Moore, Gordon | 0 | 0 |
| Berg, Paul | 0 | 0 |
| Wilson, Gayle | 0 | 0 |
| Moore, Nicholas | 0 | 0 |
| Cogan, John | 0 | 0 |
| Madigan, John | 0 | 0 |
| Hills, Carla | 0 | 0 |
| Whitley, Richard | 0 | 0 |
| Lofton, Kevin | 0 | 0 |
| Wold-Olsen, Per | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| DAVIGNON ETIENNE F | 45,000 | $47.74 |
| ALTON GREGG H | 5,500 | $48.02 |
| ALTON GREGG H | 5,500 | $15.27 |
| WASHINGTON ROBIN L | 1,929 | $47.51 |
| WASHINGTON ROBIN L | 5,000 | $0.00 |
| ALTON GREGG H | 500 | $15.27 |
| ALTON GREGG H | 500 | $47.00 |
| MARTIN JOHN C | 100,000 | $44.80 |
| MARTIN JOHN C | 66,992 | $3.70 |
| MARTIN JOHN C | 33,008 | $3.70 |
| ALTON GREGG H | 5,000 | $43.33 |
| ALTON GREGG H | 5,000 | $15.27 |
| MILLIGAN JOHN F | 2,732 | $5.88 |
| MILLIGAN JOHN F | 8,016 | $3.70 |
| MILLIGAN JOHN F | 7,000 | $4.91 |
| MARTIN JOHN C | 100,000 | $3.70 |
| MARTIN JOHN C | 100,000 | $46.16 |
| BERG PAUL | 15,000 | $46.00 |
| BERG PAUL | 15,000 | $7.26 |
| BISCHOFBERGER NORBERT W | 17,920 | $47.16 |
| BISCHOFBERGER NORBERT W | 5,600 | $0.00 |
| BISCHOFBERGER NORBERT W | 30,000 | $46.91 |
| BISCHOFBERGER NORBERT W | 30,000 | $16.01 |
| BISCHOFBERGER NORBERT W | 2,000 | $47.16 |
| MARTIN JOHN C | 2,500 | $47.12 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
